Tobira Therapeutics, Inc. Common Stock
TBRA
TBRA was delisted on the 31st of October, 2016.
33 hedge funds and large institutions have $47.9M invested in Tobira Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 1 closing their positions.
1,800% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 1
338% more capital invested
Capital invested by funds: $10.9M → $47.9M (+$37M)
120% more funds holding
Funds holding: 15 → 33 (+18)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.12M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.9M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.86M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.56M |
| 5 |
BIA
Biondo Investment Advisors
Milford,
Pennsylvania
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$969K |
| 2 |
Morgan Stanley
New York
|
-$227K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$101K |
| 4 |
Goldman Sachs
New York
|
-$81.5K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$66K |
TBRA Hedge Fund Activity: Q1 2014 in Review
33 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q1 2014, worth a combined $47.9M — up 338% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TBRA positions and 1 closed out — a net gain of 18 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.12M. The largest seller was Wexford Capital, cutting an estimated $969K.
- 33 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q1 2014, up from 15 in Q4 2013.
- Funds reported $47.9M of Tobira Therapeutics, Inc. Common Stock stock for Q1 2014, up 338% quarter-over-quarter.
- 19 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q1 2014 and 1 closed out, a net change of +18 holders.
- The largest Tobira Therapeutics, Inc. Common Stock buyer in Q1 2014 was Baker Bros. Advisors, an estimated $3.12M added.
- The largest Tobira Therapeutics, Inc. Common Stock seller in Q1 2014 was Wexford Capital, an estimated $969K sold.
Based on aggregated 13F filings for Q1 2014.